Acurx Pharmaceuticals (ACXP) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Acurx Pharmaceuticals is the larger company by market cap ($6.3 million vs $5.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | TPST |
|---|---|---|
| Share price | $1.04 | $0.287 |
| Market cap | $6.30M | $5.74M |
| 1-day change | +0.97% | -6.18% |
| YTD return | — | -90.00% |
| 1-year return | — | -91.80% |
| 5-year return | — | -99.77% |
| EPS (TTM) | $-1.90 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.97M | $-26.26M |
| 52-week high | $7.54 | $4.22 |
| 52-week low | $0.90 | $0.28 |
| Distance from 52-week high | -86.21% | -93.20% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1534.62% | +2339.02% |
| Average volume | 97.29K | 2.56M |
| Shares outstanding | 6.06M | 20.00M |
| Employees | 4 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ACXP vs TPST FAQ
Which is bigger, Acurx Pharmaceuticals or Tempest Therapeutics?
Acurx Pharmaceuticals (ACXP) is larger, with a market capitalization of $6.30M compared with $5.74M for Tempest Therapeutics (TPST).
Are Acurx Pharmaceuticals and Tempest Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.